The effect of submaximal doses of the drug Mexidol on the processes of oxidant stress and inflammation in the acute period of ischemic stroke

Authors:
A.R. Godunova, A.A. Rakhimova, O.I. Leontyeva, I.G. Talipova, R.M. Yakhin, Sh.G. Musin

GBUZ of the Republic of Tatarstan "Hospital of ambulance", Naberezhnye Chelny, Russia

Place of publication:
Journal of Neurology and Psychiatry, 2, 2018

Summary:
Purpose of the study. Track the dynamics of biochemical markers of inflammation and indicators of damage to the brain tissue in the acute period of ischemic stroke (AI) in the background of taking submaximal doses of the drug Mexidol. Material and methods. The study included 60 patients received in the first 6 hours from the onset of the disease, with verified AI on the Aspects scale 7–9 points. Patients of the main group (n = 30) received submaximal doses of Mexidol - 750 mg of the drug diluted in 250.0 ml of physiological solution, 2 times a day intravenously for 6 days. Patients of the control group (n = 30) were prescribed standard therapy. All patients were determined by biomarkers, an assessment of the neurological status within 60 minutes from the moment of receipt to the hospital and on the 7th day. Results and conclusion. In both groups, the indicators of the C-reactive protein, Interleukin-6 and fibrinogen changed slightly and did not have reliable significance in assessing the effectiveness of Mexidol. The indicators of biomarkers such as brainwater peptide and pretein plasma-A protein-A, as well as the average indicators in the NIHSS and MFI-20 scales in a group of patients receiving Mexidol, have significantly decreased compared to the control group. The results indicate a decrease in oxidant stress and signs of inflammation in the acute period of AI against the background of submaximal doses of the drug Mexidol, a decrease in the severity of neurological deficiency, and an increase in physical activity of patients. Given the time of activation of the damaged antioxidant system of the body, the recommended period of drug support is 3 months. Key words: antioxidant stress, inflammation, acute period, ischemic stroke, Mexidol.